Form 4: Lisata Therapeutics Executive Kristen K. Buck Reports Stock Transactions

Kristen K. Buck, EVP, R&D and CMO of Lisata Therapeutics, reports acquisition of restricted stock and disposition of shares to cover tax liabilities.

Summary

• On January 9, 2025, Kristen K. Buck, EVP, R&D and CMO of Lisata Therapeutics, acquired 25,000 shares of common stock as restricted stock awards.
• These awards vest in four equal installments: one-fourth on the grant date and additional one-fourths on the first, second, and third anniversaries.
• Also on January 9, 2025, Buck disposed of 2,651, 2,863 and 1,908 shares of common stock at $3.80 per share to cover tax liabilities related to vesting of restricted stock.
• On January 10, 2025, Buck disposed of 456 shares of common stock at $3.73 per share to cover tax liabilities related to vesting of restricted stock.
• Buck also acquired 13,000 stock options with an exercise price of $3.80, vesting in a similar manner to the restricted stock awards.
• Following these transactions, Buck beneficially owns 80,250 shares of common stock and 13,000 stock options.

Sentiment

Score: 6

Explanation: Neutral sentiment. The transactions are routine and related to executive compensation. The stock sales to cover taxes are a minor negative, but the grants are a positive.

Positives

• The grant of restricted stock and stock options to a key executive signals confidence in the company's future performance.

Negatives

• The sale of shares to cover tax liabilities, while common, can be perceived negatively as it reduces the executive's stake in the company.

Risks

• Executive stock sales could create short-term price volatility.

Future Outlook

The restricted stock and stock options vest over three years, incentivizing the executive to remain with the company and contribute to its long-term success.

Industry Context

Stock grants and options are common forms of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.

Comparison to Industry Standards

• Executive compensation packages in biotech companies of similar size and stage typically include a mix of salary, stock options, and restricted stock units.
• The vesting schedules for the restricted stock and stock options are fairly standard, with vesting occurring over a three to four year period.

Stakeholder Impact

• Shareholders may view the stock grants as a positive sign of management's commitment.
• Employees may be motivated by the fact that executives are incentivized to improve company performance.

Key Dates